These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 12765493)
1. Linezolid: in infants and children with severe Gram-positive infections. Lyseng-Williamson KA; Goa KL Paediatr Drugs; 2003; 5(6):419-29; discussion 430-1. PubMed ID: 12765493 [TBL] [Abstract][Full Text] [Related]
2. Linezolid: a review of its use in the management of serious gram-positive infections. Perry CM; Jarvis B Drugs; 2001; 61(4):525-51. PubMed ID: 11324682 [TBL] [Abstract][Full Text] [Related]
4. Linezolid for the treatment of resistant gram-positive cocci. Bain KT; Wittbrodt ET Ann Pharmacother; 2001 May; 35(5):566-75. PubMed ID: 11346064 [TBL] [Abstract][Full Text] [Related]
5. Linezolid--a review of the first oxazolidinone. Norrby R Expert Opin Pharmacother; 2001 Feb; 2(2):293-302. PubMed ID: 11336587 [TBL] [Abstract][Full Text] [Related]
7. Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic. Corti G; Cinelli R; Paradisi F Int J Antimicrob Agents; 2000 Dec; 16(4):527-30. PubMed ID: 11118873 [TBL] [Abstract][Full Text] [Related]
8. Use of linezolid in children: an overview of recent advances. Velissariou IM Expert Rev Anti Infect Ther; 2006 Dec; 4(6):947-52. PubMed ID: 17181410 [TBL] [Abstract][Full Text] [Related]
9. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141 [TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Chiappini E; Conti C; Galli L; de Martino M Clin Ther; 2010 Jan; 32(1):66-88. PubMed ID: 20171414 [TBL] [Abstract][Full Text] [Related]
14. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group. Kaplan SL; Patterson L; Edwards KM; Azimi PH; Bradley JS; Blumer JL; Tan TQ; Lobeck FG; Anderson DC; Pediatr Infect Dis J; 2001 May; 20(5):488-94. PubMed ID: 11368105 [TBL] [Abstract][Full Text] [Related]
15. Tedizolid: a new oxazolidinone antimicrobial. Kisgen JJ; Mansour H; Unger NR; Childs LM Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035 [TBL] [Abstract][Full Text] [Related]
16. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142 [TBL] [Abstract][Full Text] [Related]
17. Benefit-risk assessment of linezolid for serious gram-positive bacterial infections. Falagas ME; Vardakas KZ Drug Saf; 2008; 31(9):753-68. PubMed ID: 18707190 [TBL] [Abstract][Full Text] [Related]
18. Use of linezolid in pediatrics: a critical review. Dotis J; Iosifidis E; Ioannidou M; Roilides E Int J Infect Dis; 2010 Aug; 14(8):e638-48. PubMed ID: 20106697 [TBL] [Abstract][Full Text] [Related]
19. Linezolid. Narang M; Gomber S Indian Pediatr; 2004 Nov; 41(11):1129-32. PubMed ID: 15591662 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of linezolid versus comparator therapies in Gram-positive infections. Wilcox MH J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii27-35. PubMed ID: 12730140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]